529 Table
4. Treatment-Emergent Adverse Events in Placebo-Controlled Trials*
Body/System Adverse Event |
WELLBUTRIN SR 300 mg/day (n=376) |
WELLBUTRIN SR 400mg/day (n=114) |
Placebo (n=385) |
Body (General) Headache Infection Abdominal Pain Asthenia Chest pain Pain Fever |
26% 8% 3% 2% 3% 2% 1% |
25% 9% 9% 4% 4% 3% 2% |
23% 6% 2% 2% 1% 2% - |
Cardiovascular Palpitation Flushing Migraine Hot flashes |
2% 1% 1% 1% |
6% 4% 4% 3% |
2% - 1% 1% |
Digestive Dry mouth Nausea Constipation Diarrhea Anorexia Vomiting Dysphagia |
17% 13% 10% 5% 5% 4% 0% |
24% 18% 5% 7% 3% 2% 2% |
7% 8% 7% 6% 2% 2% 0% |
Musculoskeletal Myalgia Arthralgia Arthritis Twitch |
2% 1% 0% 1% |
6% 4% 2% 2% |
3% 1% 0% - |
Nervous system Insomnia Dizziness Agitation Anxiety Tremor Nervousness Somnolence |
11% 7% 3% 5% 6% 5% 2% |
16% 11% 9% 6% 3% 3% 3% |
6% 5% 2% 3% 1% 3% 2% |
16
Back a Page
Next Page
Back to Wellbutrin XL NDA Index Page
Back to Main Index Page